Opioid Analgesics — outpatient prescribing limits and indications
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.38 alerts
Get alerted when Policy 05.02.38 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage and utilization management for outpatient opioid analgesic prescriptions (immediate- and extended-release) including indications, limitations of use, acute pain duration limits, and exceptions for cancer/sickle cell/palliative/hospice patients; affects prescribers, pharmacists, and members under Wellmark/Blue Cross Blue Shield plans in Iowa.
No material clinical or coverage changes in this revision.
Coverage Criteria and Limits
Acute Pain Duration and Coverage Criteria
Covered when ALL of the following are met
See individual product limitations of use reserving opioids when alternatives are inadequate.
First fill defined by absence of a >=7-day supply in past 90 days.
Exemptions must be demonstrable in claims or claim submission.
Prior Authorization Coverage Criteria
Covered with prior authorization when the following grouped criteria are met:
Chronic pain generally >3 months
Quantity limits may apply
Initial fill rules
Initial quantity limits and routing
See IR Quantity Limits Chart Columns A/B for the applicable initial quantity limits.
Patients with prior opioid fills
Post‑initial limits when prior opioid exposure present
Use Column A and Column B in the Opioid Analgesics IR Quantity Limits Chart.
Exemptions (cancer, SCD, palliative/hospice)
Exceptions to acute limits
Multiple claim/profile checks described in policy determine routing.
Coverage criteria by pain acuity and dose
Coverage limits and durations tied to pain acuity and specific drug considerations
System rejects requests exceeding initial quantity limits and routes to prior authorization.
Insufficient evidence for long-term benefit and increased harms dose-dependent.
American Pain Society defines high dose >200 mg oral morphine equivalent.
Applies only when SCD is confirmed in claims or member health profile.
The acute pain duration limit applies only to patients with non-cancer, non-sickle-cell, non-hospice, and non-palliative pain who are identified as potential first fills of immediate‑release opioid prescriptions. Patients are limited to a maximum 7‑day supply per fill (up to 7 days of therapy in a 90‑day period) for first fills; if an incoming prescription is for more than a 7‑day supply and the patient lacks qualifying prior opioid history, the claim will reject and the member may receive a 7‑day supply or the prescriber may submit a prior authorization for additional quantity.
Acute duration and quantity limits are waived when the patient has evidence of cancer, sickle cell disease, palliative care, or hospice in claims or the member profile. Examples of qualifying evidence include a drug claim in the past year indicating treatment for cancer or sickle cell disease, a prescription claim submitted with an ICD‑10 code for cancer, sickle cell, or palliative care, an ICD‑10 diagnosis for cancer or palliative care in the member health profile within the past 365 days, any history of a sickle cell ICD‑10 diagnosis in the member profile, or a prescription claim submitted with a hospice residence code; in these cases the drug will be paid under the prescription benefit and different routing/limits apply.
Certain products indicated only for short‑term acute use have their 30‑day limit set equal to the 90‑day limit so that prescriptions must be dispensed monthly (one month at a time) rather than as three‑month supplies. The intent is to prevent fill of 3‑month supplies for these drugs and to require monthly dispensing even for mail order.
Use of meperidine is discouraged as a first‑line opioid and is not recommended for chronic pain because of the risk of accumulation of the metabolite normeperidine and associated central excitatory toxicity. Oral administration is specifically discouraged due to increased first‑pass metabolism and higher normeperidine formation; meperidine should be reserved for short‑term use of only a few days when needed and when alternatives are inadequate.
Meperidine oral solution and tablets should not be used for chronic pain because prolonged use increases the risk of normeperidine accumulation and toxicity (for example, seizures). The policy limits initial meperidine quantities to a supply corresponding to approximately 72 hours with post‑limit quantities corresponding to about 96 hours to minimize accumulation risk.
First‑fill prescriptions for IR or ER opioids for non‑cancer, non‑sickle‑cell, non‑hospice, non‑palliative pain that request more than a 7‑day supply will reject at claim adjudication. The member may receive a 7‑day supply or the prescriber may submit a prior authorization; PA criteria will be applied to requests for additional quantity.
Pentazocine (and mixed agonist‑antagonist agents) has limited clinical usefulness and is not recommended for cancer pain; because of dysphoric reactions, short duration of action, and safety concerns, these agents have a generally limited role and their monthly and three‑month limits are set the same to restrict longer supplies.
Diagnosis, Product, and Procedure Codes
| ICD-10 | Diagnosis codes indicating cancer, sickle cell disease, or palliative care used on prescription claim to exempt limits |
| ICD-10 (general) | Diagnosis codes indicating cancer, sickle cell disease, or palliative care (used to screen out limits) |
| drug-level entries | Named IR opioid formulations (e.g., codeine, hydromorphone, levorphanol, meperidine, morphine) with labeled dosing and initial/post limits expressed as tablets, mL, or suppositories equating to MME/day limits as shown in the Opioid Analgesics IR Quantity Limits Chart |
| No codes listed |
Provider Responsibilities, Prior Authorization, and Documentation
Prior Authorization Required
Prior authorization is required when an incoming prescription for an immediate‑release (IR) or extended‑release (ER) opioid represents a first fill that exceeds a 7‑day supply. Claims for a first opioid fill greater than 7 days will reject with a message indicating the patient may receive a 7‑day supply or the prescriber may submit a prior authorization (PA) for additional quantities. When the system rejects requests that exceed the initial quantity limit, the prescriber must submit a PA; the PA unit will apply the prior authorization criteria to determine coverage.
- If the patient has no record of at least an 8‑day supply of an IR or ER opioid in the past 90 days (i.e., opioid‑naïve), and the incoming prescription is for >7 days, the claim will reject and a PA is required for additional days.
- If a patient exceeds 7 days of opioid therapy for the first time in a 90‑day period, the claim will reject and a PA must be submitted for additional quantities.
- System rejects will also occur for requests exceeding initial MME‑based quantity limits; these require PA submission for review.
Diagnosis / Drug‑History Documentation for Screenout
To screen out exceptions to the acute pain duration and quantity limits, include supporting diagnosis or prescription history evidence: a prescription claim with an ICD‑10 diagnosis code for cancer, sickle cell disease, or palliative care; a hospice patient residence code on the claim; an ICD‑10 diagnosis of cancer or palliative care in the member health profile within the past 365 days; or any history of an ICD‑10 diagnosis code indicating sickle cell disease in the member health profile. A recent prescription claim for a cancer or sickle cell disease drug (within 365 days) under the prescription benefit will also route payment under that benefit and exempt duration/quantity limits.
- Acceptable screenout evidence: ICD‑10 code for cancer, sickle cell disease, or palliative care on the prescription claim.
- Acceptable screenout evidence: hospice patient residence code on the prescription claim.
- Acceptable screenout evidence: member health profile contains ICD‑10 for cancer or palliative care within past 365 days, or any history of sickle cell disease diagnosis code.
- Acceptable screenout evidence: prescription claim for a cancer or sickle cell disease drug within past 365 days.
Conservative Use and Reserving Opioids
Reserve immediate‑release opioids for patients when non‑opioid alternatives or opioid combination products have not been tolerated or have not provided adequate analgesia. Prescribers should prescribe the lowest effective dose for the shortest duration needed and consider nonopioid therapies first.
- Document justification that alternative treatments (e.g., NSAIDs, acetaminophen, physical therapy, or opioid combination products) were tried and were not tolerated or ineffective when reserving opioids.
- For opioid‑naïve patients start with the lowest effective dose and limit duration (coverage provided for up to 7 days initially for acute pain).
Risk Assessment and Follow‑Up Documentation
Before initiating and periodically during opioid therapy, evaluate and document patient risk for opioid‑related harms (e.g., history of substance use disorder, depression, prior overdose, concurrent CNS depressants, or doses ≥50 MME/day). Reassess benefits and risks within 1–4 weeks of starting therapy or dose escalation and at least every 3 months during continuation; for higher‑risk patients, reassess more frequently. If benefits do not outweigh risks, optimize other therapies and consider gradual tapering.
- Document baseline risk assessment and follow‑up plan in the medical record.
- Reassess pain, function, and adverse effects in the first month after initiation or dose increase and every 3 months thereafter (more often for higher‑risk patients).
Non-Opioid Alternatives and Conservative Use
Supply Durations, Quantity and Daily Dose Limits
Monitoring and Follow-up for Chronic Opioid Therapy
Key Definitions
Exclusions and Not Covered Uses
Use of meperidine for chronic pain is listed as not covered due to toxicity risk from normeperidine accumulation. In addition, first‑fill IR/ER opioid claims requesting a supply exceeding 7 days for non‑cancer/non‑sickle‑cell/non‑hospice/non‑palliative indications are not covered without prior authorization and will reject at the point of sale until a PA is obtained or a 7‑day supply is dispensed.
Clinical Background
Opioid analgesics are indicated for management of acute or chronic pain severe enough to require an opioid when alternative treatments are inadequate. Because of risks of addiction, misuse, and dose‑related harms, the policy emphasizes reserving listed opioid products for patients who have not tolerated or not responded to alternative options (for example, non‑opioid analgesics or opioid combination products). Exemptions to the acute duration and quantity limits exist for cancer, sickle cell disease, palliative care, and hospice as described in the program and screenout logic.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.